ARAY: Reset P/E Expectations And Guidance Withdrawal Will Shape Future Risk Balance

The analyst price target on Accuray has been cut by about $3.53 to reflect a lower implied fair value, a higher discount rate, and sharply reduced future P/E expectations, following recent downgrades where analysts cited softer growth and margin assumptions.

Analyst Commentary

Recent research on Accuray has focused on how realistic growth and margin assumptions should feed into valuation, especially after the latest downgrades and the reset in future P/E expectations.

Bullish Takeaways

Bullish analysts still see room for Accuray to execute on its existing product and customer base, which could help support earnings quality even with more conservative growth assumptions.
Some commentary points to Accuray already reflecting a good portion of the recent downgrades in its valuation, which could limit further multiple compression if execution stabilizes.
Supportive views highlight that a recalibrated P/E framework, while less aggressive, may set a lower bar for Accuray to meet or modestly exceed expectations on margins and cash generation.
Bullish analysts view the updated fair value work as creating a cleaner link between Accuray’s fundamentals and its target valuation, which may help reduce future estimate volatility.

Bearish Takeaways

Bearish analysts are focused on softer growth and margin assumptions that now feed directly into lower target valuations for Accuray, especially through reduced projected earnings power.
The higher discount rate applied in recent models signals greater perceived risk around Accuray’s execution and long term forecasts, which weighs on implied fair value.
Sharp cuts to future P/E expectations suggest that previous assumptions may have been too optimistic, leaving less room for valuation support if Accuray underdelivers on revenue or profitability.
Bears also point to the recent sequence of downgrades as a sign that the Street is still recalibrating expectations, which can keep pressure on Accuray’s valuation until there is clearer evidence on growth and margins.

What’s in the News for Accuray

Accuray and the University of Wisconsin School of Medicine and Public Health entered a new 10 year collaboration focused on advancing personalized cancer treatments using Accuray's Stellar adaptive radiation therapy platform. The work spans clinical research, education, training, and development of adaptive therapies. (Source: Key Developments)
The collaboration builds on decades of joint work that began with technology invented in the late 1980s by Professor Thomas "Rock" Mackie and his team. This technology was later commercialized as Accuray's first helical radiation delivery platform, the TomoTherapy System, and has since been refined for image quality, speed, versatility, and workflow efficiency. (Source: Key Developments)
Accuray withdrew its earnings guidance for fiscal 2026, citing geopolitical uncertainty in the Middle East that is materially affecting product shipments and service revenue, with installations in several markets in the region delayed. (Source: Key Developments)

Valuation Changes for Accuray

Fair Value: The updated target fair value has been reduced from $3.88 to $0.35, reflecting more cautious assumptions in the Accuray valuation model.
Discount Rate: The discount rate has increased from 11.35% to 12.46%, signaling higher perceived risk being applied to Accuray’s projected cash flows.
Revenue Growth: The revenue growth assumption has shifted from a projected 4.20% increase to a 0.71% decline, indicating expectations for softer top line performance in the updated view.
Profit Margin: The net profit margin expectation has moved from 12.91% to 11.88%, pointing to a slightly more conservative stance on Accuray’s long term profitability.
Future P/E: The future P/E multiple has been lowered from 11.28x to 1.40x, which significantly reduces the valuation multiple applied to Accuray’s expected earnings.

0 views

Catalysts

About Accuray

Accuray develops and manufactures advanced radiation therapy systems that enable precise, personalized treatment of cancer and other diseases.

What are the underlying business or industry changes driving this perspective?

Global demand for precision and adaptive radiotherapy is increasing as cancer incidence rises and clinicians seek to reduce toxicity, supporting multi year growth in system placements and recurring service revenue.
The launch of the Stellar platform and ongoing innovation in online adaptive radiotherapy position Accuray to participate in higher value segments of the radiation oncology market, which may influence average selling prices and product gross margins over time.
Deepening clinical and academic collaborations, such as the memorandum of understanding with the University of Wisconsin, can support evidence generation and training that expand utilization, influencing procedure volumes and long term service revenue.
Management’s transformation plan, including restructuring actions and cost optimization, is designed to affect adjusted EBITDA margins, with a focus on earnings power even in a modest top line growth environment.
Growth of the installed base in developed and high growth international regions, combined with demonstrated pricing power on service contracts, supports a more predictable, higher margin recurring revenue mix that can affect cash flow stability and net margins.

NasdaqGS:ARAY Earnings & Revenue Growth as at Dec 2025

Assumptions

How have these above catalysts been quantified?

Analysts are assuming Accuray's revenue will remain fairly flat over the next 3 years.
Analysts are not forecasting that Accuray will become profitable in next 3 years. To represent the Analyst Price Target as a Future PE Valuation we will estimate Accuray's profit margin will increase from -10.8% to the average US Medical Equipment industry of 11.9% in 3 years.
If Accuray's profit margin were to converge on the industry average, you could expect earnings to reach $49.8 million (and earnings per share of $0.36) by about June 2029, up from -$46.1 million today.
In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 1.4x on those 2029 earnings, up from -0.8x today. This future PE is lower than the current PE for the US Medical Equipment industry at 25.7x.
Analysts expect the number of shares outstanding to grow by 5.58% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 12.46%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

A prolonged slowdown in capital equipment purchasing in key regions such as EIMEA and China, whether due to geopolitical or macroeconomic pressures, could keep product revenue below expectations and limit overall top line growth.
Sustained pressure from tariffs and unfavorable geographic and product mix, particularly a higher proportion of lower margin emerging market deals, could constrain gross margins and delay the path to sustainable profitability and stronger net margins.
If the transformation and restructuring plan fails to deliver the anticipated cost savings and operational efficiencies, higher operating expenses and restructuring charges could continue to weigh on adjusted EBITDA and earnings.
Execution risk in converting the large order backlog into installations, especially given long sales cycles and regional timing issues, could result in revenue being pushed out or lost altogether, undermining cash flow and earnings visibility.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of $0.35 for Accuray based on their expectations of its future earnings growth, profit margins and other risk factors.
In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $419.5 million, earnings will come to $49.8 million, and it would be trading on a PE ratio of 1.4x, assuming you use a discount rate of 12.5%.
Given the current share price of $0.32, the analyst price target of $0.35 is 9.4% higher.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on Accuray?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Rising Precision Radiotherapy Demand Will Support Stronger Long Term Earnings Power